$NRIX
Nurix Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022033709 Filed on October 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2021 Q3
Revenue $10.79M $10.25M
YoY Change 5.26% 150.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.748M $8.343M
YoY Change 16.84% 92.24%
% of Gross Profit
Research & Development $47.76M $30.91M
YoY Change 54.54% 63.19%
% of Gross Profit
Depreciation & Amortization $1.457M $745.0K
YoY Change 95.57% 35.45%
% of Gross Profit
Operating Expenses $57.51M $39.25M
YoY Change 46.52% 68.62%
Operating Profit -$46.72M -$29.00M
YoY Change 61.11%
Interest Expense $1.009M $39.00K
YoY Change 2487.18% -94.26%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$45.71M -$28.96M
YoY Change 57.85% 56.39%
Income Tax $0.00 -$100.0K
% Of Pretax Income
Net Earnings -$45.71M -$28.84M
YoY Change 58.52% 55.72%
Net Earnings / Revenue -423.58% -281.26%
Basic Earnings Per Share -$0.90 -$0.65
Diluted Earnings Per Share -$0.90 -$649.8K
COMMON SHARES
Basic Shares Outstanding 50.87M 44.37M
Diluted Shares Outstanding 50.87M 44.37M

Balance Sheet

Concept 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $344.5M $343.9M
YoY Change 0.17% -2.88%
Cash & Equivalents $47.56M $147.4M
Short-Term Investments $296.9M $196.5M
Other Short-Term Assets $10.39M $9.343M
YoY Change 11.24% 50.69%
Inventory
Prepaid Expenses
Receivables $0.00 $5.000M
Other Receivables $0.00 $204.0K
Total Short-Term Assets $354.9M $358.4M
YoY Change -1.0% -1.55%
LONG-TERM ASSETS
Property, Plant & Equipment $16.50M $9.569M
YoY Change 72.44% 46.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $69.13M $121.5M
YoY Change -43.1% 197.02%
Other Assets $4.092M $3.580M
YoY Change 14.3% 1835.14%
Total Long-Term Assets $104.5M $134.6M
YoY Change -22.4% 181.74%
TOTAL ASSETS
Total Short-Term Assets $354.9M $358.4M
Total Long-Term Assets $104.5M $134.6M
Total Assets $459.3M $493.1M
YoY Change -6.84% 19.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.053M $3.861M
YoY Change 56.77% 6.92%
Accrued Expenses $25.11M $11.57M
YoY Change 117.0% 62.94%
Deferred Revenue $36.34M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.50M $50.68M
YoY Change 33.19% 23.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $49.29M $67.18M
YoY Change -26.62% 7639.29%
Total Long-Term Liabilities $49.29M $67.18M
YoY Change -26.62% 7639.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.50M $50.68M
Total Long-Term Liabilities $49.29M $67.18M
Total Liabilities $116.8M $117.9M
YoY Change -0.9% 13.05%
SHAREHOLDERS EQUITY
Retained Earnings -$354.5M -$183.2M
YoY Change 93.5% 118.66%
Common Stock $700.8M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $342.5M $375.2M
YoY Change
Total Liabilities & Shareholders Equity $459.3M $493.1M
YoY Change -6.84% 19.71%

Cashflow Statement

Concept 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$45.71M -$28.84M
YoY Change 58.52% 55.72%
Depreciation, Depletion And Amortization $1.457M $745.0K
YoY Change 95.57% 35.45%
Cash From Operating Activities -$46.31M -$29.97M
YoY Change 54.5% 388.14%
INVESTING ACTIVITIES
Capital Expenditures -$3.418M -$1.865M
YoY Change 83.27% 11.68%
Acquisitions
YoY Change
Other Investing Activities -$59.66M -$10.37M
YoY Change 475.52% -90.26%
Cash From Investing Activities -$63.08M -$12.23M
YoY Change 415.71% -88.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.4M 1.552M
YoY Change 7336.02% -99.3%
NET CHANGE
Cash From Operating Activities -46.31M -29.97M
Cash From Investing Activities -63.08M -12.23M
Cash From Financing Activities 115.4M 1.552M
Net Change In Cash 6.023M -40.65M
YoY Change -114.82% -138.28%
FREE CASH FLOW
Cash From Operating Activities -$46.31M -$29.97M
Capital Expenditures -$3.418M -$1.865M
Free Cash Flow -$42.89M -$28.11M
YoY Change 52.6% 528.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
204000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10393000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9194000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
354871000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
311118000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13848000
dei Entity Central Index Key
EntityCentralIndexKey
0001549595
dei Document Type
DocumentType
10-Q
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity File Number
EntityFileNumber
001-39398
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Document Period End Date
DocumentPeriodEndDate
2022-08-31
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
NRIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47147781
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47556000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6000000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9748000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
138391000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3742000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4092000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6053000
CY2022Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
19609000
CY2021Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
14549000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5496000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3847000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
36342000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
41212000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67500000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7745000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
59022000
CY2022Q3 us-gaap Liabilities
Liabilities
116793000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47147781
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47147781
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44664371
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44664371
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
45000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563757000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-608000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220892000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000
CY2022Q3 us-gaap Assets
Assets
459338000
CY2021Q4 us-gaap Assets
Assets
476771000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6650000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66258000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41548000
CY2021Q4 us-gaap Liabilities
Liabilities
134469000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
47000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-354535000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
342545000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22384000
CY2022Q3 us-gaap Revenues
Revenues
10791000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47761000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79903000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8343000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
57509000
us-gaap Operating Income Loss
OperatingIncomeLoss
-79933000
us-gaap Interest And Other Income
InterestAndOtherIncome
528000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-79405000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
87000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28835000
us-gaap Net Income Loss
NetIncomeLoss
-133643000
us-gaap Net Income Loss
NetIncomeLoss
-79492000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50868542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44374389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46835776
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42344420
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42344420
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28835000
us-gaap Net Income Loss
NetIncomeLoss
-133643000
us-gaap Net Income Loss
NetIncomeLoss
-79492000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3134000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-146000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-136777000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79638000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
290269000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
394000
CY2021Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
40000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.85
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44374389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46835776
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-657000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-89000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46366000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28924000
us-gaap Operating Expenses
OperatingExpenses
102287000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-46718000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28997000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45709000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1009000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
39000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
459338000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
39249000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4313000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-89000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-123000
us-gaap Profit Loss
ProfitLoss
-133643000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3730000
us-gaap Share Based Compensation
ShareBasedCompensation
19834000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1076000
CY2021Q3 nrix Lease Commencement Date
LeaseCommencementDate
2021-12-01
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7745000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50868542
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44374389
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46835776
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42344420
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
NURIX THERAPEUTICS, INC.
dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
660-5320
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80506000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
296922000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
215214000
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
69125000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
137189000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14005000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16501000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
286000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2833000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
700775000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
476771000
CY2021Q3 us-gaap Revenues
Revenues
10252000
us-gaap Revenues
Revenues
31844000
us-gaap Revenues
Revenues
22354000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30906000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28630000
us-gaap Operating Expenses
OperatingExpenses
167021000
us-gaap Operating Income Loss
OperatingIncomeLoss
-135177000
us-gaap Interest And Other Income
InterestAndOtherIncome
1534000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28958000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-133643000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50868542
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1043000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2700000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-38000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24275000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
270133000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150157000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
241000
CY2021Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
104000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3944000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-19000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26382000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
398178000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
584000
CY2021Q3 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
49000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1017000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28835000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
375217000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
424000
CY2022Q1 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
47000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1064000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6071000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1458000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-42533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
305917000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
432000
CY2022Q2 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
35000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6775000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1019000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-45401000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
266739000
CY2022Q3 nrix Adjustments To Additional Paid In Capital Pre Funded Warrants Issuance Costs
AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuanceCosts
234000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
94759000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19328000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
CY2022Q3 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
32000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
891000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6988000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-657000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
342545000
us-gaap Profit Loss
ProfitLoss
-79492000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2033000
us-gaap Share Based Compensation
ShareBasedCompensation
10957000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1100000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-128000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4041000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2439000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3642000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6040000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
984000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
727000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-22344000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10647000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3679000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2432000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
4189000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2837000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121852000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53454000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212455000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
257813000
nrix Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
6994000
nrix Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
194324000
nrix Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
183890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9679000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4799000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27810000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-71728000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
94942000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19400000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150157000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1030000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1166000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1955000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2060000
nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117327000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153382000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32335000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28200000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48457000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147726000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1726000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
839000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
114000
nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
193000
nrix Issuance Costs Related To Pre Funded Warrants Included In Accrued Expenses And Other Liabilities
IssuanceCostsRelatedToPreFundedWarrantsIncludedInAccruedExpensesAndOtherLiabilities
183000
nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
72000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47556000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
147440000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
901000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
286000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48457000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
147726000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-354500000
CY2022Q3 nrix Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
413600000
CY2022Q3 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
19609000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s marketable securities consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</p>
CY2021Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
14549000
CY2022Q3 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2022Q3 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2021Q3 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2021Q3 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13343000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3342000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10903000
CY2020Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
8276000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2439000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2432000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2837000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
34651000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26219000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18150000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14879000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16501000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1500000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3700000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000000.0
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10312000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8854000
CY2022Q3 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
6267000
CY2021Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
4158000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1335000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
41000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
75000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1654000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
659000
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0
CY2022Q3 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0
nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0
CY2021Q3 nrix Impairment Loss On Marketable Securities
ImpairmentLossOnMarketableSecurities
0
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-04-30
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320
CY2021Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
CY2022Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2035-03-01
CY2022Q1 nrix Operating Lease Rent Payable Per Month
OperatingLeaseRentPayablePerMonth
205000
CY2022Q1 nrix Percentage Of Increase Of Annual Rent
PercentageOfIncreaseOfAnnualRent
0.03
CY2022Q1 nrix Lessee Operating Lease Liability To Be Paid Year One Per Month
LesseeOperatingLeaseLiabilityToBePaidYearOnePerMonth
154000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1500000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
4400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
us-gaap Operating Lease Payments
OperatingLeasePayments
5198000
us-gaap Operating Lease Payments
OperatingLeasePayments
2784000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5060000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2097000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1376000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6976000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7422000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4330000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2670000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2750000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
22556000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48080000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
525000
CY2022Q3 nrix Lessee Operating Lease Liability Undiscounted Lease Payments Related To Lease
LesseeOperatingLeaseLiabilityUndiscountedLeasePaymentsRelatedToLease
34314000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13241000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5496000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13241000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18041033
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9476306
CY2022Q3 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
27424
CY2022Q3 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
200000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
85900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2021Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-45709000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-28835000
us-gaap Net Income Loss
NetIncomeLoss
-133643000
us-gaap Net Income Loss
NetIncomeLoss
-79492000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50868542
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44374389
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46835776
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42344420
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9019337
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5732861

Files In Submission

Name View Source Status
0001564590-22-033709-index-headers.html Edgar Link pending
0001564590-22-033709-index.html Edgar Link pending
0001564590-22-033709.txt Edgar Link pending
0001564590-22-033709-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-10q_20220831.htm Edgar Link pending
nrix-20220831.xsd Edgar Link pending
nrix-ex102_182.htm Edgar Link pending
nrix-ex103_181.htm Edgar Link pending
nrix-ex104_180.htm Edgar Link pending
nrix-ex105_179.htm Edgar Link pending
nrix-ex106_183.htm Edgar Link pending
nrix-ex311_6.htm Edgar Link pending
nrix-ex312_7.htm Edgar Link pending
nrix-ex321_8.htm Edgar Link pending
nrix-20220831_cal.xml Edgar Link unprocessable
nrix-20220831_def.xml Edgar Link unprocessable
nrix-20220831_lab.xml Edgar Link unprocessable
nrix-20220831_pre.xml Edgar Link unprocessable
nrix-10q_20220831_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable